Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. 

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumor necrosis factor exposure. 

Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis. 

Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. 

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. 

Rheumatoid arthritis secondary nonresponders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.